Please ensure Javascript is enabled for purposes of website accessibility

Is Inovio Pharmaceuticals a Screaming Buy?

By George Budwell - Updated Feb 17, 2020 at 10:09AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors may want to think twice before buying this vaccine stock on the heels of the COVID-19 threat.

DNA vaccine and immunotherapy company Inovio Pharmaceuticals (INO 6.91%) has been a red-hot stock during the opening weeks of 2020. The biotech's push to develop a vaccine against the novel coronavirus, COVID-19, in record time has sparked an avalanche of interest in its stock. One of the big reasons is that Inovio announced last week that researchers at its San Diego facility were able to construct a vaccine for COVID-19 in just a matter of hours after gaining access to the virus' genetic sequence. The company thus hopes to begin human trials for the experimental vaccine as soon as this summer, according to a recent interview with CEO J. Joseph Kim. 

What's the big deal? COVID-19 has already spread to 29 countries, caused over 1,600 fatalities in mainland China, and effectively shut down some major global supply chains. What's more, this deadly respiratory disease exhibits several traits such as an extensive incubation phase that may result in its becoming endemic, similar to seasonal outbreaks of the flu. In other words, COVID-19 may not simply evaporate for the most part like other severe coronavirus strains, such as the Middle East respiratory syndrome. In that event, a vaccine or an antiviral therapy will be absolutely essential in the battle against this highly infectious, and sometimes fatal, respiratory ailment.

A person in a suit holding three yellow wooden blocks that spell out buy in red capital letters.

Image source: Getty Images.

Should investors pounce on Inovio's shares in response to this viral threat? Let's take a closer look at the bull and bear cases for this biotech stock to find out.

A breakdown of Inovio's COVID-19 prospects 

If COVID-19 evolves into an endemic respiratory disease, the commercial opportunity could be quite staggering. Flu vaccines, after all, currently represent a $2 billion a year market. Now, COVID-19 will likely never morph into that kind of behemoth market, but it could very well end up supporting one or more vaccines that generate several hundred million in annual sales, especially if it becomes a serious problem in affluent western nations like the United States. So, in a sense, there is a solid rationale supporting Inovio's 25.7% jump since this viral outbreak began to garner headlines earlier this year. 

The bad news is that Inovio has never actually developed a commercial-stage vaccine. Despite being in business for 40 years, the company is only now on the cusp of generating late-stage data for one of its DNA-based therapies. Specifically, Inovio is slated to roll out top-line data for VGX-3100 as a treatment for cervical dysplasia in the fourth-quarter of 2020.

Another worrying sign is that this isn't the first time Inovio's stock has skyrocketed in response to an infectious disease threat. In 2016, for instance, the biotech's shares took flight after it announced plans to tackle the Zika virus. Per the company's latest clinical update in early 2020, however, its Zika virus product candidate hasn't even made it past a phase 1 trial yet. So investors should probably take this hype over a COVID-19 virus vaccine with a huge grain of salt.  

Time to buy?

If your sole purpose is to own a company likely to benefit from the COVID-19 threat, Inovio probably isn't your best bet. The company has never brought a product to market in four decades, much to the detriment of long-suffering shareholders. Since going public, in fact, Inovio's stock has produced a negative return on capital of 92.7%. Perhaps this story will change for the better with a positive late-stage readout for VGX-3100 later this year. But until then, investors should probably curb their enthusiasm. 


George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$2.63 (6.91%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.